OBJECTIVE: The Wnt/APC/beta-catenin signaling pathway, which includes frizzled-related protein (FRZB), plays a critical role in the development of colorectal cancer, and recent evidence suggests that the functional polymorphism, FRZB Arg324Gly, may be associated with risk for this disease. To determine if this finding could be replicated, we investigated the association between two FRZB polymorphisms (Arg324Gly and Arg200Trp) and the risk of colorectal adenoma and cancer in nested case-control studies. METHODS: Participants consisted of 1,709 adenoma cases, 620 cancer cases, and 1,849 controls within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CI) for the associations with colorectal neoplasia. RESULTS: No association was observed for either polymorphism or any haplotypes with colorectal adenoma or colorectal cancer (p>0.05 for all). CONCLUSION: Our study does not support the previously observed association between the FRZB 324Gly variant and colorectal cancer risk. However, further study of additional genetic variants within this pathway is still warranted, given the important role of the Wnt signaling pathway in colorectal carcinogenesis.
OBJECTIVE: The Wnt/APC/beta-catenin signaling pathway, which includes frizzled-related protein (FRZB), plays a critical role in the development of colorectal cancer, and recent evidence suggests that the functional polymorphism, FRZB Arg324Gly, may be associated with risk for this disease. To determine if this finding could be replicated, we investigated the association between two FRZB polymorphisms (Arg324Gly and Arg200Trp) and the risk of colorectal adenoma and cancer in nested case-control studies. METHODS:Participants consisted of 1,709 adenoma cases, 620 cancer cases, and 1,849 controls within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CI) for the associations with colorectal neoplasia. RESULTS: No association was observed for either polymorphism or any haplotypes with colorectal adenoma or colorectal cancer (p>0.05 for all). CONCLUSION: Our study does not support the previously observed association between the FRZB 324Gly variant and colorectal cancer risk. However, further study of additional genetic variants within this pathway is still warranted, given the important role of the Wnt signaling pathway in colorectal carcinogenesis.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Bernice R Packer; Meredith Yeager; Brian Staats; Robert Welch; Andrew Crenshaw; Maureen Kiley; Andrew Eckert; Michael Beerman; Edward Miller; Andrew Bergen; Nathaniel Rothman; Robert Strausberg; Stephen J Chanock Journal: Nucleic Acids Res Date: 2004-01-01 Impact factor: 16.971
Authors: Sonja I Berndt; John D Potter; Aditi Hazra; Meredith Yeager; Gilles Thomas; Karen W Makar; Robert Welch; Amanda J Cross; Wen-Yi Huang; Robert E Schoen; Edward Giovannucci; Andrew T Chan; Stephen J Chanock; Ulrike Peters; David J Hunter; Richard B Hayes Journal: Hum Mol Genet Date: 2008-06-04 Impact factor: 6.150
Authors: Kalai S Shanmugam; Hermann Brenner; Michael Hoffmeister; Jenny Chang-Claude; Barbara Burwinkel Journal: Carcinogenesis Date: 2007-04-09 Impact factor: 4.944
Authors: John Loughlin; Barbara Dowling; Kay Chapman; Lucy Marcelline; Zehra Mustafa; Lorraine Southam; Athena Ferreira; Cathleen Ciesielski; Dennis A Carson; Maripat Corr Journal: Proc Natl Acad Sci U S A Date: 2004-06-21 Impact factor: 11.205